FDA
Business & Industry
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
 - Pfizer to acquire Metsera and its next-generation obesity portfolio
 - Roche enters into a definitive merger agreement to acquire 89bio
 - Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
 - Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
 
Research & Development
- Making cancer vaccines more personal
 - Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer
 - Bias can lead to better therapies
 - Epigenetic reprogramming safely modifies multiple genes in T Cells simultaneously for CAR-T therapies
 - Study helps to understand the role of genetics in the body weight
 - Personalized brain stimulation offers new hope for people with hard-to-treat epilepsy
 - New trial finds diabetes drug and nasal insulin improve brain health in early Alzheimer's disease
 
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
 - New insights into T and B cells offer hope for autoimmune disease sufferers
 - SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
 - SAE Media Group's 6th annual 3D Cell Culture Conference
 - CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
 - 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
 - CPHI Excellence in Pharma Award Winners 2022
 
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
 - FDA approves new treatment for hemophilia A or B
 - FDA approves nasal spray influenza vaccine for self- or caregiver-administration
 - FDA approves first nasal spray for treatment of anaphylaxis
 - FDA approves nonsteroidal treatment for Duchenne muscular dystrophy